Optimizing IGF-I for skeletal muscle therapeutics

Growth Hormone and IGF Research

Volumn 24, Issue 5, 2014, Pages 157-163

  Philippou, Anastassios ^a   Barton, Elisabeth R ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Anabolism; Hypertrophy; Isoforms; Post translational processing; Satellite cells

Indexed keywords

SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; ISOPROTEIN;

CARBOXY TERMINAL SEQUENCE; DRUG BINDING; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG RETENTION; EXTRACELLULAR MATRIX; GENE; GENE DELIVERY SYSTEM; GLYCOSYLATION; HUMAN; IGF1 GENE; MUSCLE ATROPHY; MUSCLE GROWTH; MUSCLE INJURY; MUSCLE MASS; MUSCLE STRENGTH; NEUROMUSCULAR DISEASE; NONHUMAN; REVIEW; SARCOPENIA; SATELLITE CELL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE REPAIR; AGONISTS; ANIMAL; CHEMISTRY; DRUG EFFECTS; MUSCULAR DISEASES; PATHOLOGY; PHYSIOLOGY; REGENERATION; SKELETAL MUSCLE SATELLITE CELL;

ANIMALS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SKELETAL; MUSCULAR DISEASES; PROTEIN ISOFORMS; RECEPTOR, IGF TYPE 1; REGENERATION; SATELLITE CELLS, SKELETAL MUSCLE;

EID: 84908080576     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2014.06.003     Document Type: Review

References (109)

1. Borasio G.D., Robberecht W., Leigh P.N., et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998, 51:583-586.
2. Butterfield G.E., Thompson J., Rennie M.J., Marcus R., Hintz R.L., Hoffman A.R. Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am. J. Physiol. 1997, 272:E94-E99.
3. Cusi K., DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J. Clin. Endocrinol. Metab. 2000, 85:3077-3084.
4. Friedlander A.L., Butterfield G.E., Moynihan S., et al. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J. Clin. Endocrinol. Metab. 2001, 86:1496-1503.
5. Lai E.C., Felice K.J., Festoff B.W., et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997, 49:1621-1630.
6. Mauras N., O'Brien K.O., Welch S., et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J. Clin. Endocrinol. Metab. 2000, 85:1686-1694.
7. Moxley R.T. Potential for growth factor treatment of muscle disease. Curr. Opin. Neurol. 1994, 7:427-434.
8. Nagano I., Shiote M., Murakami T., et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol. Res. 2005, 27:768-772.
9. Sorenson E.J., Windbank A.J., Mandrekar J.N., et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71:1770-1775.
10. Thompson J.L., Butterfield G.E., Gylfadottir U.K., et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J. Clin. Endocrinol. Metab. 1998, 83:1477-1484.
11. Waters D., Danska J., Hardy K., et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1996, 125:865-872.
12. Heatwole C.R., Eichinger K.J., Friedman D.I., et al. Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Arch. Neurol. 2011, 68:37-44.
13. Adamo M.L., Neuenschwander S., LeRoith D., Roberts C.T. Structure, expression, and regulation of the IGF-I gene. Adv. Exp. Med. Biol. 1993, 343:1-11.
14. Barton E.R. The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair. Appl. Physiol. Nutr. Metab. 2006, 31:791-797.
15. Rotwein P., Pollock K.M., Didier D.K., Krivi G.G. Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J. Biol. Chem. 1986, 261:4828-4832.
16. Shimatsu A., Rotwein P. Mosaic evolution of the insulin-like growth factors. Organization, sequence, and expression of the rat insulin-like growth factor I gene. J. Biol. Chem. 1987, 262:7894-7900.
17. Adamo M.L., Neuenschwander S., LeRoith D., Roberts C.T. Structure, expression, and regulation of the IGF-1 gene. Adv. Exp. Med. Biol. 1993, 343:1-11.
18. Wallis M. New insulin-like growth factor (IGF)-precursor sequences from mammalian genomes: the molecular evolution of IGFs and associated peptides in primates. Growth Hormon. IGF Res. 2009, 19:12-23.
19. Duguay S.J. Post-translational processing of insulin-like growth factors. Horm. Metab. Res. 1999, 31:43-49.
20. Duguay S.J., Milewski W.M., Young B.D., Nakayama K., Steiner D.F. Processing of wild-type and mutant proinsulin-like growth factor-IA by subtilisin-related proprotein convertases. J. Biol. Chem. 1997, 272:6663-6670.
21. Conover C.A., Baker B.K., Hintz R.L. Cultured human fibroblasts secrete insulin-like growth factor IA prohormone. J. Clin. Endocrinol. Metab. 1989, 69:25-30.
22. Conover C.A., Baker B.K., Bale L.K., Clarkson J.T., Liu F., Hintz R.L. Human hepatoma cells synthesize and secrete insulin-like growth factor Ia prohormone under growth hormone control. Regul. Pept. 1993, 48:1-8.
23. Durzynska J., Philippou A., Brisson B.K., Nguyen-McCarty M., Barton E.R. The pro-forms of insulin-like growth factor I (IGF-I) are predominant in skeletal muscle and alter IGF-I receptor activation. Endocrinology 2013, 154:1215-1224.
24. Wilson H.E., Westwood M., White A., Clayton P.E. Monoclonal antibodies to the carboxy-terminal Ea sequence of pro-insulin-like growth factor-IA (proIGF-IA) recognize proIGF-IA secreted by IM9 B-lymphocytes. Growth Hormon. IGF Res. 2001, 11:10-17.
25. Bach M.A., Roberts C.T., Smith E.P., LeRoith D. Alternative splicing produces messenger RNAs encoding insulin-like growth factor-I prohormones that are differentially glycosylated in vitro. Mol. Endocrinol. 1990, 4:899-904.
26. Adams T.E., Epa V.C., Garrett T.P., Ward C.W. Structure and function of the type 1 insulin-like growth factor receptor. Cell. Mol. Life Sci. 2000, 57:1050-1093.
27. Duan C., Ren H., Gao S. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen. Comp. Endocrinol. 2010, 167:344-351.
28. Brisson B.K., Barton E.R. New modulators for IGF-I activity within IGF-I processing products. Front. Endocrinol. (Lausanne) 2013, 4:42.
29. Barton E.R., Park S., James J.K., et al. Deletion of muscle GRP94 impairs both muscle and body growth by inhibiting local IGF production. FASEB J. 2012, 26:3691-3702.
30. Sjogren K., Liu J.L., Blad K., et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7088-7092.
31. Yakar S., Liu J.L., Stannard B., et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7324-7329.
32. Turner J.D., Rotwein P., Novakofski J., Bechtel P.J. Induction of mRNA for IGF-I and -II during growth hormone-stimulated muscle hypertrophy. Am. J. Physiol. 1988, 255:E513-E517.
33. Barton-Davis E.R., Shoturma D.I., Musaro A., Rosenthal N., Sweeney H.L. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15603-15607.
34. Coleman M.E., DeMayo F., Yin K.C., et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 1995, 270:12109-12116.
35. Musaro A., McCullagh K., Paul A., et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 2001, 27:195-200.
36. Ostrovsky O., Eletto D., Makarewich C., Barton E.R., Argon Y. Glucose regulated protein 94 is required for muscle differentiation through its control of the autocrine production of insulin-like growth factors. Biochim. Biophys. Acta 2010, 1803:333-341.
37. Elis S., Wu Y., Courtland H.W., et al. Increased serum IGF-1 levels protect the musculoskeletal system but are associated with elevated oxidative stress markers and increased mortality independent of tissue igf1 gene expression. Aging Cell 2011, 10:547-550.
38. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 2002, 23:824-854.
39. Hede M.S., Salimova E., Piszczek A., et al. E-peptides control bioavailability of IGF-1. PLoS ONE 2012, 7:e51152.
40. Brisson B.K., Spinazzola J., Park S., Barton E.R. Viral expression of insulin-like growth factor I E-peptides increases skeletal muscle mass but at the expense of strength. Am. J. Physiol. Endocrinol. Metab. 2014, 306:E965-E974.
41. Durzynska J., Wardzinski A., Koczorowska M., Gozdzicka-Jozefiak A., Barton E.R. Human Eb peptide: not just a by-product of pre-pro-IGF1b processing?. Horm. Metab. Res. 2013, 45:415-422.
42. Brisson B.K., Barton E.R. Insulin-like growth factor-I E-peptide activity is dependent on the IGF-I receptor. PLoS ONE 2012, 7:e45588.
43. Fornaro M., Hinken A.C., Needle S., et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am. J. Physiol. Endocrinol. Metab. 2014, 306:E150-E156.
44. Park S., Brisson B.K., Liu M., Spinazzola J.M., Barton E.R. Mature IGF-I excels in promoting functional muscle recovery from disuse atrophy compared with pro-IGF-IA. J. Appl. Physiol. 1985, 116(2014):797-806.
45. Philippou A., Stavropoulou A., Sourla A., et al. Characterization of a rabbit antihuman mechano growth factor (MGF) polyclonal antibody against the last 24 amino acids of the E domain. In Vivo 2008, 22(1):27-35.
46. Yuasa K., Masuda T., Yoshikawa C., Nagahama M., Matsuda Y., Tsuji A. Subtilisin-like proprotein convertase PACE4 is required for skeletal muscle differentiation. J. Biochem. 2009, 146:407-415.
47. Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem. J. 1997, 327(Pt 1):209-215.
48. Entingh-Pearsall A., Kahn C.R. Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J. Biol. Chem. 2004, 279:38016-38024.
49. Kristensen C., Wiberg F.C., Andersen A.S. Specificity of insulin and insulin-like growth factor I receptors investigated using chimeric mini-receptors. Role of C-terminal of receptor alpha subunit. J. Biol. Chem. 1999, 274:37351-37356.
50. Christoffersen C.T., Bornfeldt K.E., Rotella C.M., et al. Negative cooperativity in the insulin-like growth factor-I receptor and a chimeric IGF-I/insulin receptor. Endocrinology 1994, 135:472-475.
51. Mothe I., Tartare S., Kowalski-Chauvel A., Kaliman P., Van Obberghen E., Ballotti R. Tyrosine kinase activity of a chimeric insulin-like-growth-factor-1 receptor containing the insulin receptor C-terminal domain. Comparison with the tyrosine kinase activities of the insulin and insulin-like-growth-factor-1 receptors using a cell-free system. Eur. J. Biochem. 1995, 228:842-848.
52. Tartare S., Mothe I., Kowalski-Chauvel A., Breittmayer J.P., Ballotti R., Van Obberghen E. Signal transduction by a chimeric insulin-like growth factor-1 (IGF-1) receptor having the carboxyl-terminal domain of the insulin receptor. J. Biol. Chem. 1994, 269:11449-11455.
53. Urso B., Cope D.L., Kalloo-Hosein H.E., et al. Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor receptor in 3T3-L1 adipocytes. J. Biol. Chem. 1999, 274:30864-30873.
54. Urso B., Niesler C.U., O'Rahilly S., Siddle K. Comparison of anti-apoptotic signalling by the insulin receptor and IGF-I receptor in preadipocytes and adipocytes. Cell. Signal. 2001, 13:279-285.
55. Pete G., Fuller C.R., Oldham J.M., et al. Postnatal growth responses to insulin-like growth factor I in insulin receptor substrate-1-deficient mice. Endocrinology 1999, 140:5478-5487.
56. Sesti G., Federici M., Hribal M.L., Lauro D., Sbraccia P., Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001, 15:2099-2111.
57. Withers D.J., Burks D.J., Towery H.H., Altamuro S.L., Flint C.L., White M.F. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat. Genet. 1999, 23:32-40.
58. Siddle K. Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances. Front. Endocrinol. (Lausanne) 2012, 3:34.
59. Shi J., Luo L., Eash J., Ibebunjo C., Glass D.J. The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev. Cell 2011, 21:835-847.
60. Kalista S., Schakman O., Gilson H., et al. The type 1 insulin-like growth factor receptor (IGF-IR) pathway is mandatory for the follistatin-induced skeletal muscle hypertrophy. Endocrinology 2012, 153:241-253.
61. Spangenburg E.E., Le Roith D., Ward C.W., Bodine S.C. A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy. J. Physiol. 2008, 586:283-291.
62. Mauro A. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 1961, 9:493-495.
63. Hawke T.J., Garry D.J. Myogenic satellite cells: physiology to molecular biology. J. Appl. Physiol. 1985, 91(2001):534-551.
64. Allen R.E., Sheehan S.M., Taylor R.G., Kendall T.L., Rice G.M. Hepatocyte growth factor activates quiescent skeletal muscle satellite cells in vitro. J. Cell. Physiol. 1995, 165:307-312.
65. Golding J.P., Calderbank E., Partridge T.A., Beauchamp J.R. Skeletal muscle stem cells express anti-apoptotic ErbB receptors during activation from quiescence. Exp. Cell Res. 2007, 313:341-356.
66. Tatsumi R., Anderson J.E., Nevoret C.J., Halevy O., Allen R.E. HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev. Biol. 1998, 194:114-128.
67. Barton-Davis E.R., Shoturma D.I., Sweeney H.L. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol. Scand. 1999, 167:301-305.
68. Adams G.R. Invited review: autocrine/paracrine IGF-I and skeletal muscle adaptation. J. Appl. Physiol. 1985, 93(2002):1159-1167.
69. Moss F.P., Leblond C.P. Satellite cells as the source of nuclei in muscles of growing rats. Anat. Rec. 1971, 170:421-435.
70. Garry D.J., Meeson A., Elterman J., et al. Myogenic stem cell function is impaired in mice lacking the forkhead/winged helix protein MNF. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5416-5421.
71. Hurme T., Kalimo H. Activation of myogenic precursor cells after muscle injury. Med. Sci. Sports Exerc. 1992, 24:197-205.
72. Karalaki M., Fili S., Philippou A., Koutsilieris M. Muscle regeneration: cellular and molecular events. In Vivo 2009, 23:779-796.
73. Morgan J.E., Partridge T.A. Muscle satellite cells. Int. J. Biochem. Cell Biol. 2003, 35:1151-1156.
74. Robertson T.A., Papadimitriou J.M., Grounds M.D. Fusion of myogenic cells to the newly sealed region of damaged myofibres in skeletal muscle regeneration. Neuropathol. Appl. Neurobiol. 1993, 19:350-358.
75. Schultz E. Satellite cell behavior during skeletal muscle growth and regeneration. Med. Sci. Sports Exerc. 1989, 21:S181-S186.
76. Seale P., Rudnicki M.A. A new look at the origin, function, and "stem-cell" status of muscle satellite cells. Dev. Biol. 2000, 218:115-124.
77. Adams G.R., Haddad F. The relationships among IGF-1, DNA content, and protein accumulation during skeletal muscle hypertrophy. J. Appl. Physiol. 1985, 81(1996):2509-2516.
78. Adams G.R., McCue S.A. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J. Appl. Physiol. 1985, 84(1998):1716-1722.
79. Grounds M.D., White J.D., Rosenthal N., Bogoyevitch M.A. The role of stem cells in skeletal and cardiac muscle repair. J. Histochem. Cytochem. 2002, 50:589-610.
80. McCall G.E., Allen D.L., Linderman J.K., et al. Maintenance of myonuclear domain size in rat soleus after overload and growth hormone/IGF-I treatment. J. Appl. Physiol. 1985, 84(1998):1407-1412.
81. Jennische E., Hansson H.A. Regenerating skeletal muscle cells express insulin-like growth factor I. Acta Physiol. Scand. 1987, 130:327-332.
82. Jennische E., Skottner A., Hansson H.A. Satellite cells express the trophic factor IGF-I in regenerating skeletal muscle. Acta Physiol. Scand. 1987, 129:9-15.
83. Tollefsen S.E., Lajara R., McCusker R.H., Clemmons D.R., Rotwein P. Insulin-like growth factors (IGF) in muscle development. Expression of IGF-I, the IGF-I receptor, and an IGF binding protein during myoblast differentiation. J. Biol. Chem. 1989, 264:13810-13817.
84. Caroni P., Schneider C. Signaling by insulin-like growth factors in paralyzed skeletal muscle: rapid induction of IGF1 expression in muscle fibers and prevention of interstitial cell proliferation by IGF-BP5 and IGF-BP4. J. Neurosci. 1994, 14:3378-3388.
85. Barton E.R., DeMeo J., Lei H. The insulin-like growth factor (IGF)-I E-peptides are required for isoform-specific gene expression and muscle hypertrophy after local IGF-I production. J. Appl. Physiol. 1985, 108(2010):1069-1076.
86. Schertzer J.D., Lynch G.S. Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury. Gene Ther. 2006, 13:1657-1664.
87. Qaisar R., Renaud G., Morine K., Barton E.R., Sweeney H.L., Larsson L. Is functional hypertrophy and specific force coupled with the addition of myonuclei at the single muscle fiber level?. FASEB J. 2012, 26:1077-1085.
88. Barton E.R. Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. J. Appl. Physiol. 1985, 100(2006):1778-1784.
89. McCarthy J.J., Mula J., Miyazaki M., et al. Effective fiber hypertrophy in satellite cell-depleted skeletal muscle. Development 2011, 138:3657-3666.
90. Mauras N., Martinez V., Rini A., Guevara-Aguirre J. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J. Clin. Endocrinol. Metab. 2000, 85:3036-3042.
91. Stevens-Lapsley J.E., Ye F., Liu M., et al. Impact of viral-mediated IGF-I gene transfer on skeletal muscle following cast immobilization. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E730-E740.
92. Ye F., Mathur S., Liu M., et al. Overexpression of insulin-like growth factor-1 attenuates skeletal muscle damage and accelerates muscle regeneration and functional recovery after disuse. Exp. Physiol. 2013, 98:1038-1052.
93. Criswell D.S., Booth F.W., DeMayo F., Schwartz R.J., Gordon S.E., Fiorotto M.L. Overexpression of IGF-I in skeletal muscle of transgenic mice does not prevent unloading-induced atrophy. Am. J. Physiol. 1998, 275:E373-E379.
94. Song Y.H., Li Y., Du J., Mitch W.E., Rosenthal N., Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J. Clin. Invest. 2005, 115:451-458.
95. Martins K.J., Gehrig S.M., Naim T., et al. Intramuscular administration of PEGylated IGF-I improves skeletal muscle regeneration after myotoxic injury. Growth Hormon. IGF Res. 2013, 23:128-133.
96. Pelosi L., Giacinti C., Nardis C., et al. Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB J. 2007, 21:1393-1402.
97. Takahashi T., Ishida K., Itoh K., et al. IGF-I gene transfer by electroporation promotes regeneration in a muscle injury model. Gene Ther. 2003, 10:612-620.
98. Menetrey J., Kasemkijwattana C., Day C.S., et al. Growth factors improve muscle healing in vivo. J. Bone Joint Surg. Br. Vol. 2000, 82:131-137.
99. Hammers D.W., Sarathy A., Pham C.B., Drinnan C.T., Farrar R.P., Suggs L.J. Controlled release of IGF-I from a biodegradable matrix improves functional recovery of skeletal muscle from ischemia/reperfusion. Biotechnol. Bioeng. 2012, 109:1051-1059.
100. Nagano I., Ilieva H., Shiote M., et al. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 2005, 235:61-68.
101. Dobrowolny G., Giacinti C., Pelosi L., et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005, 168:193-199.
102. Saenger S., Goeldner C., Frey J.R., et al. PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders. Growth Hormon. IGF Res. 2011, 21:292-303.
103. Barton E.R., Morris L., Musaro A., Rosenthal N., Sweeney H.L. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 2002, 157:137-148.
104. Shavlakadze T., White J., Hoh J.F., Rosenthal N., Grounds M.D. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol. Ther. 2004, 10:829-843.
105. Gehrig S.M., van der Poel C., Hoeflich A., Naim T., Lynch G.S., Metzger F. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy. Growth Hormon. IGF Res. 2012, 22:69-75.
106. Metzger F., Sajid W., Saenger S., et al. Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I). J. Biol. Chem. 2011, 286:19501-19510.
107. Gregorevic P., Plant D.R., Leeding K.S., Bach L.A., Lynch G.S. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am. J. Pathol. 2002, 161:2263-2272.
108. Gregorevic P., Plant D.R., Lynch G.S. Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. Muscle Nerve 2004, 30:295-304.
109. Gehrig S.M., Ryall J.G., Schertzer J.D., Lynch G.S. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Exp. Physiol. 2008, 93:1190-1198.